Compared to other biomarkers like NfL, GFAP may serve as a more effective early indicator of astrocyte reactivity and neurodegeneration in preclinical AD, making it a promising tool for identifying individuals at risk before clinical symptoms emerge [61,66]. Here, GFAP is linked to Alzheimer disease.